Conditions: 97.1% · date of analysis.
I would like to know the limits of what can be inferred from this.
What I am trying to avoid is over-reading a single result, which I have done before.
What would I need in addition before this supported a decision?
97.1 per cent is a statement about area, and the other 2.9 per cent is everything the detector saw and did not assign to your peak. Read it as 97.1 of every 100 units of peak area at whatever wavelength was used, not as 97.1 per cent of the mass in the vial. With the date of analysis attached you can at least see how the figure was produced, which is the difference between a measurement and a claim. What it still does not tell you is content: how many milligrams are actually there.
The single most important distinction is between what purity measures — the fraction of detected material that is your target — and what you actually want to know — how much of the material in the vial is your target.
Mass on column affects detector linearity and peak overlap — overloading broadens peaks and hides neighbours, while underloading improves resolution but loses sensitivity.
| Component | Typical share | Counted in purity? | Counted in content? |
|---|---|---|---|
| Target peptide | 88–94 % | Yes, as main peak | Yes |
| Related impurities | 1–3 % | Yes, as other peaks | No |
| Counter-ion (TFA or acetate) | 2–8 % | No | No |
| Residual water | 2–6 % | No | No |
| Bulking agent, if present | 0–40 % | No | No |
Column pore size affects mass transfer — a 100 Angstrom packing on a 5 kDa peptide restricts diffusion, broadening the peak and potentially hiding small impurities in the shoulders.
The ICH Q3A impurity thresholds and the relevant pharmacopoeial chapters all specify method validation requirements that almost no research-grade certificate claims to meet.
I would be careful about over-reading a single measurement — treat it as a data point, not as ground truth.
Compare purity within a single laboratory on the same method, never across laboratories.
Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.
Shop standardsSpecifically, understanding purity requires separating the chemistry from the method from the reporting convention, and the three are not independent.
Sample solvent strength affects peak shape — if you inject in strong solvent on a gradient starting in weak solvent, the solvent peak can distort your main peak or create a false shoulder.
The part that matters: buffer versus acid in the mobile phase changes the ionisation state of basic and acidic residues, shifting retention and selectivity — same vial, potentially different separation.
Inter-laboratory studies on identical peptide material routinely find half-a-per-cent to a full-per-cent spreads in reported purity on the same sample.
Worth noting that method standardisation is poor in the research-grade space compared to pharmaceutical work, so identical-looking methods can produce different results.
The practical summary: ask for the chromatogram and the method, and ignore the headline number until you have both.
edited 25 Feb 2026 by ines_brandt — corrected a unit error in the worked example
To be exact about it, reporting threshold is convention and not chemistry, which is why two certificates with different thresholds disagree by a tenth of a point or more.
Tailing factor measures peak shape, and a badly tailing peak spreads into the region where small impurities live, forcing tangent-skim integration that assigns tail area to the main peak.
Detection wavelength matters because 214 nm sees the peptide backbone while 280 nm sees only aromatic side chains — so truncation impurities lacking a tryptophan are invisible at 280 nm.
The Arrhenius relationship for peptide degradation is the basis of accelerated stability testing and also governs how quickly methods drift with temperature.
The limitation is that single-digit micro-impurities become invisible at typical reporting thresholds, so "no impurities detected" means "none above one in two thousand."
If you are ranking vendors, specify a method and have all samples tested at the same place.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.